Hazel H. Szeto

Hazel H. Szeto

Auto-generated profile, based on publicly available information

Hazel H. Szeto

Social Profit Network Research Lab, Menlo Park, California

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2013 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
ABAlexander V. Birk
Alexander V. Birk
SLShaoyi Liu
Shaoyi Liu
YSYi Soong
Yi Soong
WMWilliam Mills
William Mills
PSPradeep Singh
Pradeep Singh
HSHazel H. Szeto
Hazel H. Szeto
Ischemia causes AKI as a result of ATP depletion, and rapid recovery of ATP on reperfusion is important to minimize tissue damage. ATP recovery is often delayed, however, because ischemia destroys the mitochondrial cristae membranes required for mitochondrial ATP synthesis. The mitochondria-targeted compound SS-31 accelerates ATP recovery after ischemia and reduces AKI, but its mechanism of action remains unclear. Here, we used a polarity-sensitive fluorescent analog of SS-31 to demonstrate that SS-31 binds with high affinity to cardiolipin, an anionic phospholipid expressed on the inner mitochondrial membrane that is required for cristae formation. In addition, the SS-31/cardiolipin complex inhibited cytochrome c peroxidase activity, which catalyzes cardiolipin peroxidation and results in mitochondrial damage during ischemia, by protecting its heme iron. Pretreatment of rats with SS-31 protected cristae membranes during renal ischemia and prevented mitochondrial swelling. Prompt recovery of ATP on reperfusion led to rapid repair of ATP-dependent processes, such as restoration of the actin cytoskeleton and cell polarity. Rapid recovery of ATP also inhibited apoptosis, protected tubular barrier function, and mitigated renal dysfunction. In conclusion, SS-31, which is currently in clinical trials for ischemia-reperfusion injury, protects mitochondrial cristae by interacting with cardiolipin on the inner mitochondrial membrane.

1 May 2014 in Longevity & Healthspan
Verified
Journal Article
Open access
PDF file
DDDao-Fu Dai
Dao-Fu Dai
YCYing Ann Chiao
Ying Ann Chiao
David J. MarcinekDavid J. Marcinek
David J. Marcinek
HSHazel H Szeto
Hazel H Szeto
PRPeter Rabinovitch
Peter Rabinovitch
The free radical theory of aging proposes that reactive oxygen species (ROS)-induced accumulation of damage to cellular macromolecules is a primary driving force of aging and a major determinant of lifespan. Although this theory is one of the most popular explanations for the cause of aging, several experimental rodent models of antioxidant manipulation have failed to affect lifespan. Moreover, antioxidant supplementation clinical trials have been largely disappointing. The mitochondrial theory of aging specifies more particularly that mitochondria are both the primary sources of ROS and the primary targets of ROS damage. In addition to effects on lifespan and aging, mitochondrial ROS have been shown to play a central role in healthspan of many vital organ systems. In this article we review the evidence supporting the role of mitochondrial oxidative stress, mitochondrial damage and dysfunction in aging and healthspan, including cardiac aging, age-dependent cardiovascular diseases, skeletal muscle aging, neurodegenerative diseases, insulin resistance and diabetes as well as age-related cancers. The crosstalk of mitochondrial ROS, redox, and other cellular signaling is briefly presented. Potential therapeutic strategies to improve mitochondrial function in aging and healthspan are reviewed, with a focus on mitochondrial protective drugs, such as the mitochondrial antioxidants MitoQ, SkQ1, and the mitochondrial protective peptide SS-31.

1 November 2016 in Kidney International
Verified
Journal Article
Closed access
HSHazel H. Szeto
Hazel H. Szeto
SLShaoyi Liu
Shaoyi Liu
YSYi Soong
Yi Soong
NANazia Alam
Nazia Alam
GPGlen T. Prusky
Glen T. Prusky
SSSurya V. Seshan
Surya V. Seshan

1 June 2011 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
HSHazel H. Szeto
Hazel H. Szeto
SLShaoyi Liu
Shaoyi Liu
YSYi Soong
Yi Soong
DWDunli Wu
Dunli Wu
SDShaun F. Darrah
Shaun F. Darrah
SSSurya V. Seshan
Surya V. Seshan
The burst of reactive oxygen species (ROS) during reperfusion of ischemic tissues can trigger the opening of the mitochondrial permeability transition (MPT) pore, resulting in mitochondrial depolarization, decreased ATP synthesis, and increased ROS production. Rapid recovery of ATP upon reperfusion is essential for survival of tubular cells, and inhibition of oxidative damage can limit inflammation. SS-31 is a mitochondria-targeted tetrapeptide that can scavenge mitochondrial ROS and inhibit MPT, suggesting that it may protect against ischemic renal injury. Here, in a rat model of ischemia-reperfusion (IR) injury, treatment with SS-31 protected mitochondrial structure and respiration during early reperfusion, accelerated recovery of ATP, reduced apoptosis and necrosis of tubular cells, and abrogated tubular dysfunction. In addition, SS-31 reduced medullary vascular congestion, decreased IR-mediated oxidative stress and the inflammatory response, and accelerated the proliferation of surviving tubular cells as early as 1 day after reperfusion. In summary, these results support MPT as an upstream target for pharmacologic intervention in IR injury and support early protection of mitochondrial function as a therapeutic maneuver to prevent tubular apoptosis and necrosis, reduce oxidative stress, and reduce inflammation. SS-31 holds promise for the prevention and treatment of acute kidney injury.

28 March 2014 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
ABA V Birk
A V Birk
WCW M Chao
W M Chao
CBC Bracken
C Bracken
JWJ David Warren
J David Warren
HSH H Szeto
H H Szeto